This FAQ summarizes a Special Report discussion on how two experts decide who is a candidate for testosterone therapy in women, from symptoms and context to hormone state vs age.
News|Articles|May 5, 2026
A recap of ACOG's 75th Annual Clinical & Scientific Meeting
Author(s)Joshua Fitch, Senior Editor
Fact checked by: Benjamin P. Saylor, Tracy Ann Politowicz
Take a look back at our coverage (so far) of the 2026 ACOG meeting in Washington, DC
Advertisement
Advertisement
From May 1-3, 2026, the Contemporary OB/GYN editorial team was on location in Washington, DC, to highlight the latest clinical developments out of the
Related to this article
This FAQ summarizes a Special Report discussion of what the evidence does and does not establish about testosterone therapy in women.
Real-world data show maternal RSVpreF vaccination was 82% effective against infant RSV LRTI hospitalization through 3 months.
Matthew Nudy, MD, on estrogen's cardiovascular effects, risk assessment, and hormone therapy safety in younger menopausal women.
Lisa Taylor-Swanson, PhD, on a pilot in which integrative group medical visits improved menopause symptoms, knowledge, and self-efficacy.
Peter Hsin, BS, discusses a meta-analysis linking perioperative ketamine to lower early postpartum depressive symptoms after cesarean delivery.
A recap of the top video interviews from Contemporary OB/GYN's coverage of The Menopause Society 2026 Annual Meeting in San Diego.
The FDA granted accelerated approval to Voceryq to reduce papilloma excision surgeries in adults with recurrent respiratory papillomatosis.
Advertisement
Advertisement